ADC Therapeutics SA (ADCT) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1236895,
    "name": "ADC Therapeutics SA",
    "stock_name": "ADC Therapeutics SA",
    "full_name": "ADC Therapeutics SA",
    "name_url": "stocks-analysis/adc-therapeutics-sa",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "3.54",
    "chg": -0.41,
    "chgp": "-10.38%",
    "dir": -1,
    "prev_price": "3.95",
    "mcapval": "405.08",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "CH0499880968",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.4 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/adc-therapeutics-sa-1236895-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "ADC Therapeutics SA Hits New 52-Week High of $4.80",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/adc-therapeutics-sa-hits-new-52-week-high-of-480-3662000",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ADCTherapeutics_priceRelatedfactors_3662000.png",
        "date": "2025-10-31 16:23:49",
        "description": "ADC Therapeutics SA achieved a new 52-week high of USD 4.80 on October 30, 2025, reflecting a strong performance over the past year. With a market capitalization of USD 405 million, the company operates in the Pharmaceuticals & Biotechnology sector, despite being loss-making and lacking dividends."
      },
      {
        "title": "ADC Therapeutics SA Hits New 52-Week High of $4.67",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/adc-therapeutics-sa-hits-new-52-week-high-of-467-3601664",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ADCTherapeutics_priceRelatedfactors_3601664.png",
        "date": "2025-10-07 21:56:25",
        "description": "ADC Therapeutics SA has achieved a new 52-week high of USD 4.67, marking a significant milestone for the microcap company in the Pharmaceuticals & Biotechnology sector. Over the past year, it has gained 21.7%, showcasing effective management despite being loss-making and navigating a challenging market landscape."
      },
      {
        "title": "ADC Therapeutics SA Hits New 52-Week High of USD 4.31",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/adc-therapeutics-sa-hits-new-52-week-high-of-usd-431-3595663",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ADCTherapeutics_priceRelatedfactors_3595663.png",
        "date": "2025-10-06 17:38:37",
        "description": "ADC Therapeutics SA achieved a new 52-week high of USD 4.31 on October 3, 2025, significantly up from its low of USD 1.05. With a market cap of USD 405 million, the company has a strong return on equity of 84.56% and a unique financial structure reflected in its debt-to-equity ratio."
      },
      {
        "title": "ADC Therapeutics SA Hits New 52-Week High of USD 4.07",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/adc-therapeutics-sa-hits-new-52-week-high-of-usd-407-3586060",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ADCTherapeutics_priceRelatedfactors_3586060.png",
        "date": "2025-10-01 16:41:49",
        "description": "ADC Therapeutics SA has achieved a new 52-week high, reflecting a significant increase from its previous low. The company, with a market capitalization of USD 405 million, operates in the Pharmaceuticals & Biotechnology industry and demonstrates strong return on equity, despite its loss-making status and unique financial metrics."
      },
      {
        "title": "Is ADC Therapeutics SA technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-adc-therapeutics-sa-technically-bullish-or-bearish-3547363",
        "imagepath": "",
        "date": "2025-09-20 19:53:39",
        "description": "As of 8 September 2025, the technical trend for ADC Therapeutics SA has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish signal from Bollinger Bands on both weekly and monthly timeframes. However, the KST and Dow Theory indicators are mildly bearish on the monthly timeframe, indicating some caution. \n\nIn terms of performance, ADC Therapeutics has outperformed the S&P 500 over the past week and month, with returns of 1.80% and 4.63% respectively, while the S&P 500 returned 1.05% and 2.33%. However, the longer-term returns show significant underperformance over 3 years and 5 years compared to the S&P 500...."
      },
      {
        "title": "Is ADC Therapeutics SA overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-adc-therapeutics-sa-overvalued-or-undervalued-3543754",
        "imagepath": "",
        "date": "2025-09-20 18:27:46",
        "description": "As of 3 August 2021, the valuation grade for ADC Therapeutics SA moved from does not qualify to risky. The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of -1.62, an EV to EBIT of -5.11, and an EV to EBITDA of -5.24, all indicating significant financial distress. In comparison to peers, ADC Therapeutics has a less favorable EV to EBITDA ratio than G1 Therapeutics, Inc. at -9.6487 and Alpha Teknova, Inc. at -14.9899, which further underscores its challenging position.\n\nDespite a strong year-to-date stock return of 70.35% compared to the S&P 500's 12.22%, the long-term performance is concerning, with a 5-year return of -92.55% versus the S&P 500's 96.61%. This stark contrast suggests that while there may be short-term gains, the overall valuation and financial health of ADC Therapeutics remain precarious...."
      }
    ],
    "total": 11,
    "sid": "1236895",
    "stock_news_url": "https://www.marketsmojo.com/news/adc-therapeutics-sa-1236895"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

ADC Therapeutics SA Hits New 52-Week High of $4.80

2025-10-31 16:23:49

ADC Therapeutics SA achieved a new 52-week high of USD 4.80 on October 30, 2025, reflecting a strong performance over the past year. With a market capitalization of USD 405 million, the company operates in the Pharmaceuticals & Biotechnology sector, despite being loss-making and lacking dividends.

ADC Therapeutics SA Hits New 52-Week High of $4.67

2025-10-07 21:56:25

ADC Therapeutics SA has achieved a new 52-week high of USD 4.67, marking a significant milestone for the microcap company in the Pharmaceuticals & Biotechnology sector. Over the past year, it has gained 21.7%, showcasing effective management despite being loss-making and navigating a challenging market landscape.

ADC Therapeutics SA Hits New 52-Week High of USD 4.31

2025-10-06 17:38:37

ADC Therapeutics SA achieved a new 52-week high of USD 4.31 on October 3, 2025, significantly up from its low of USD 1.05. With a market cap of USD 405 million, the company has a strong return on equity of 84.56% and a unique financial structure reflected in its debt-to-equity ratio.

ADC Therapeutics SA Hits New 52-Week High of USD 4.07

2025-10-01 16:41:49

ADC Therapeutics SA has achieved a new 52-week high, reflecting a significant increase from its previous low. The company, with a market capitalization of USD 405 million, operates in the Pharmaceuticals & Biotechnology industry and demonstrates strong return on equity, despite its loss-making status and unique financial metrics.

Is ADC Therapeutics SA technically bullish or bearish?

2025-09-20 19:53:39

As of 8 September 2025, the technical trend for ADC Therapeutics SA has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish signal from Bollinger Bands on both weekly and monthly timeframes. However, the KST and Dow Theory indicators are mildly bearish on the monthly timeframe, indicating some caution. In terms of performance, ADC Therapeutics has outperformed the S&P 500 over the past week and month, with returns of 1.80% and 4.63% respectively, while the S&P 500 returned 1.05% and 2.33%. However, the longer-term returns show significant underperformance over 3 years and 5 years compared to the S&P 500....

Is ADC Therapeutics SA overvalued or undervalued?

2025-09-20 18:27:46

As of 3 August 2021, the valuation grade for ADC Therapeutics SA moved from does not qualify to risky. The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of -1.62, an EV to EBIT of -5.11, and an EV to EBITDA of -5.24, all indicating significant financial distress. In comparison to peers, ADC Therapeutics has a less favorable EV to EBITDA ratio than G1 Therapeutics, Inc. at -9.6487 and Alpha Teknova, Inc. at -14.9899, which further underscores its challenging position. Despite a strong year-to-date stock return of 70.35% compared to the S&P 500's 12.22%, the long-term performance is concerning, with a 5-year return of -92.55% versus the S&P 500's 96.61%. This stark contrast suggests that while there may be short-term gains, the overall valuation and financial health of ADC Therapeutics remain precarious....

View All News